Table 1.
Baseline characteristics
| Total | Total symptom distress scores (TSDS) | P‐value | Physical symptom scores (PHS) | P‐value | Psychological symptom scores (PSS) | P‐value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Low (0‐35) n = 1471 |
High (36‐90) n = 572 |
Low (0‐23) n = 1654 |
High (24‐60) n = 545 |
Low (0‐7) n = 1664 |
High (8‐20) n = 535 |
|||||
| Age, mean ± SD | 65.0 ± 10.0 | 65.3 ± 9.9 | 64.4 ± 10.3 | .007 | 65.4 ± 9.8 | 64.0 ± 10.4 | .006 | 65.3 ± 9.94 | 64.4 ± 10.1 | .07 |
| Male, n (%) | 1123 (55.0) | 836 (56.8) | 287 (50.2) | .007 | 835 (56.8) | 288 (50.2) | .007 | 819 (56.6) | 304 (51.0) | .02 |
| Income quintile, n (%) | ||||||||||
| Lowest | 316 (15.5) | 215 (14.6) | 101 (17.6) | .04 | 215 (14.6) | 101 (17.6) | .002 | 209 (14.4) | 107 (17.9) | .01 |
| Medium to low | 346 (16.9) | 249 (16.9) | 97 (17.0) | 252 (17.2) | 94 (16.4) | 236 (16.3) | 110 (18.5) | |||
| Middle | 373 (18.3) | 268 (18.2) | 105 (18.4) | 277 (18.9) | 96 (16.7) | 270 (18.7) | 103 (17.3) | |||
| Medium to high | 408 (20.0) | 301 (20.5) | 107 (18.7) | 293 (20.0) | 115 (20.0) | 292 (20.2) | 116 (19.5) | |||
| Highest | 427 (20.9) | 326 (22.2) | 101 (17.6) | 327 (22.3) | 100 (17.4) | 327 (22.6) | 100 (16.8) | |||
| Unknown | 173 (8.4) | 112 (7.6) | 61 (10.7) | 105 (7.2) | 68 (11.9) | 113 (7.8) | 60 (10.1) | |||
| Rurality, n (%) | ||||||||||
| Urban | 1745 (85.4) | 1251 (85.0) | 494 (86.4) | .74 | 1255 (85.4) | 490 (85.3) | .99 | 1218 (84.2) | 527 (88.4) | .04 |
| Rural | 280 (13.7) | 207 (14.1) | 73 (12.8) | 201 (13.7) | 79 (13.8) | 214 (14.8) | 66 (11.1) | |||
| Unknown | 18 (0.9) | 13 (0.9) | 5 (0.8) | 13 (0.9) | 5 (0.9) | 15 (1.0) | <5 | |||
| Charlson‐Deyo Score, n (%) | ||||||||||
| 0 | 1339 (65.5) | 934 (63.5) | 405 (70.8) | .001 | 933 (63.5) | 406 (70.7) | .0001 | 921 (63.7) | 418 (70.1) | <.001 |
| 1 | 47 (2.3) | 30 (2.0) | 17 (3.0) | 27 (1.8) | 20 (3.5) | 31 (2.1) | 16 (2.7) | |||
| 2+ | 657 (32.2) | 507 (34.5) | 150 (26.2) | 509 (34.7) | 148 (25.8) | 495 (34.2) | 162 (27.2) | |||
| Previous radiation, n (%) | 311 (15.2) | 234 (15.9) | 77 (13.5) | .17 | 226 (15.4) | 85 (14.8) | .75 | 228 (15.8) | 83 (13.9) | .30 |
| Previous pancreatic resection, n (%) | 383 (18.8) | 309 (21.0) | 74 (12.9) | <.001 | 318 (21.7) | 65 (11.3) | <.001 | 300 (20.7) | 83 (18.9) | <.001 |
| Previous adjuvant gemcitabine, n (%) | 120 (5.9) | 98 (6.6) | 22 (3.9) | .015 | 100 (6.8) | 20 (3.5) | .004 | 88 (6.1) | 32 (5.4) | .5 |
| Treatment regimen, n (%) | ||||||||||
| Gemcitabine | 1103 (54.0) | 757 (51.5) | 346 (60.5) | .001 | 759 (51.7) | 344 (59.9) | .002 | 767 (53.0) | 336 (56.4) | .14 |
| FOLFIRINOX | 809 (39.6) | 621 (42.2) | 188 (32.9) | 617 (42.0) | 192 (33.5) | 592 (40.9) | 217 (36.4) | |||
| Gemcitabine nab‐paclitaxel | 131 (6.4) | 93 (6.3) | 38 (6.6) | 93 (6.3) | 38 (6.6) | 88 (4.31) | 43 (7.21) | |||
| Follow‐up (months), mean ± SD | 9.2 ± 9.8 | 10.1 ± 10.2 | 6.9 ± 8.1 | <.001 | 10.2 ± 10.2 | 6.6 ± 8.1 | <.001 | 9.6 ± 10.0 | 8.0 ± 9.1 | <.001 |
| First‐line duration (months), mean ± SD | 4.5 ± 5.3 | 5.0 ± 5.6 | 3.3 ± 4.2 | <.001 | 5.0 ± 5.5 | 3.3 ± 4.3 | <.001 | 4.8 ± 5.5 | 3.9 ± 4.7 | <.001 |
| Time to first‐line treatment (mo), mean | 4.8 ± 0.22 | 4.9 ± 0.3 | 4.5 ± 0.4 | .40 | 5.0 ± 0.3 | 4.3 ± 0.4 | .15 | 4.6 ± 0.2 | 5.1 ± 0.5 | .4 |
Abbreviation: SD, standard deviation.